Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ZEVRA THERAPEUTICS, INC. (KMPH)
|
Add to portfolio |
|
|
|
| Price: |
$8.65
| | Metrics |
| OS: |
33.9
|
M
| |
-47
|
% ROE
|
| Market cap: |
$294
|
M
| |
-144
|
% ROIC
|
|
Net cash:
|
$74.7
|
M
| |
$2.20
|
per share
|
|
EV:
|
$219
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($34.6)
|
M
| |
|
|
|
EBIT
|
($35.4)
|
M
| |
|
|
| EPS |
($0.94)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 10.5 | 28.7 | 13.3 | 12.8 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -63.5% | 115.6% | 3.5% | | | | | |
| Cost of goods sold | 0.3 | 2.1 | 2.1 | 2.9 | 1.6 | 0.0 | 0.0 | 0.0 |
| Gross profit | 10.1 | 26.6 | 11.2 | 9.9 | -1.6 | 0.0 | 0.0 | 0.0 |
| Gross margin | 96.7% | 92.8% | 83.9% | 77.1% | | | | |
| Research and development | 19.6 | 10.2 | 8.8 | 19.4 | 41.8 | 20.6 | 20.5 | 13.9 |
| General and administrative | 15.3 | 8.7 | 7.9 | 10.8 | 12.5 | 12.8 | 14.0 | 8.9 |
| EBIT | -24.8 | 7.7 | -5.6 | -20.3 | -55.9 | -33.4 | -69.9 | -22.8 |
| EBIT margin | -237.5% | 27.0% | -42.2% | -158.4% | | | | |
| Pre-tax income | -42.3 | -8.5 | -12.8 | -24.5 | -56.6 | -43.4 | -16.5 | -54.6 |
| Income taxes | -0.8 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | 1.9% | | 0.3% | 0.1% | 0.2% | 0.1% | 0.1% | |
| Net income | -41.5 | -62.9 | -12.8 | -24.5 | -56.5 | -43.4 | -16.5 | -54.7 |
| Net margin | -397.2% | -219.5% | -96.0% | -191.0% | | | | |
| |
| Diluted EPS | ($1.20) | ($2.11) | ($3.21) | ($13.23) | ($3.15) | ($2.96) | ($1.13) | ($7.42) |
| Shares outstanding (diluted) | 34.5 | 29.8 | 4.0 | 1.9 | 17.9 | 14.7 | 14.6 | 7.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|